Home > Insider Trading > Filing (0001493152-22-023510)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1357459	Palisade Bio Inc.	PALI	Biological Products, (No Disgnostic Substances) (2836)	522007292

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1851034	David John Finley	7750 El Camino Real, Suite 5200 Carlsbad, CA 92009	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01	Acquisiton	2022-08-16	100,000	$0.25	121,896	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series 1 Common Stock Purchase Warrant	Acquisiton	2022-08-16	100,000	$0.00	100,000	$0.25
Common Stock	Series 2 Common Stock Purchase Warrant	Acquisiton	2022-08-16	100,000	$0.00	100,000	$0.25

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,000		2023-08-16	No	4	P	Direct
100,000		2027-08-16	No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.01	38,867	Indirect	By FCW Investments, LLC

Footnotes

Represents common shares underlying 100,000 Units of Issuer purchased by Reporting Person ("Units") in Underwritten Offering with each Unit containing (i) one share of common stock, (ii) one Series 1 Warrant and (iii) One Series 2 Warrant at a price per Unit of $0.25.
Reporting Person is the managing member of FCW Investments LLC and has the sole investment and voting power over the securities held by this entity.
Represents Series 1 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 1 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.
Represents Series 2 Common Stock Purchase Warrants received as part of the Units purchased by Reporting Person. The Series 2 Warrants are exercisable upon receipt of stockholder approval per Nasdaq rules, which has not been obtained as of the date of this Form 4.